人類乳突病毒檢測在子宮頸癌篩檢中的初步成果：探索性研究

Preliminary outcomes of Human Papillomavirus DNA testing in cervical cancer screening: A pilot study

高風險人類乳突病毒（HR-HPV）是子宮頸癌的致病因子。HR-HPV testing為世界衛生組織建議的第一線篩檢工具之一。國內現今缺乏HR-HPV testing篩檢的結果，本研究目的為評估primary HPV DNA testing與co-testing的篩檢效能。由實驗室資訊系統中，納入接受子宮頸癌篩檢病人，收集HR-HPV testing、Pap test與組織切片診斷結果，以組織切片診斷為參考標準，計算HR-HPV testing與co-testing的診斷效能。HR-HPV testing偵測出高惡性度鱗狀細胞上皮內病變（含）以上敏感度為96.3%，co-testing敏感度為91.8%。根據研究結果，HR-HPV testing與co-testing推測為敏感的篩檢工具。

High risk human papillomavirus (HR-HPV) is the causative agent of cervical cancer. HR-HPV testing is currently one of the first-line screening tools recommended by the World Health Organization. There is a paucity of data regarding HR-HPV screening outcomes in Taiwan. The purpose of this study was to evaluate the efficacy of primary HPV DNA testing and co-testing. Patients screened for cervical cancer were enrolled from the laboratory information system, and the diagnostic results of HR-HPV testing, Pap test, and histopathology were collected. In this study, we employed histopathology as the reference standard. The sensitivity of HR-HPV testing for detecting high-grade squamous intraepithelial lesion (or worse) was 96.3%, and the sensitivity of co-testing was 91.8%. According to the outcomes of our study, HR-HPV testing and co-testing are presumed to be sensitive screening tools.